{
    "clinical_study": {
        "@rank": "57042", 
        "arm_group": {
            "arm_group_label": "PQR309", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is a Phase I, open label study to determine the Maximum Tolerated Dose(MTD) and\n      the Recommended Phase II Dose (RP2D) in patients with advanced solid tumors."
        }, 
        "brief_title": "A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumors", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed diagnosis of advanced solid tumor for which\n             no therapy of proven efficacy is available.\n\n          -  Age \u2265 18\n\n          -  Evidence of tumor progression with measurable or evaluable disease.\n\n          -  Use of adequate contraceptive measures for male patients.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1.\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Concomitant anticancer therapy (e.g., chemotherapy, radiotherapy, hormonal,\n             immunotherapy, biological response modifier, signal transduction inhibitors)\n\n          -  Patients with a history of myocardial infarction or coronary artery bypass within the\n             last 3 years.\n\n          -  Patients with severe/unstable angina, coronary/peripheral arterial bypass,\n             symptomatic congestive heart failure NYHA Class 3 or 4, hypertension BP>150/100mmHg.\n\n          -  Pre-diagnosed diabetes mellitus.\n\n          -  Fasting glucose > 7.0 mmol/L or HbA1c > 6%."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940133", 
            "org_study_id": "PQR309-001", 
            "secondary_id": "2013-003441-42"
        }, 
        "intervention": {
            "arm_group_label": "PQR309", 
            "description": "Dosing will be orally, once a day for the duration of the trial.", 
            "intervention_name": "PQR309", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 14, 2014", 
        "location": {
            "contact": {
                "email": "natasa.cmiljanovic@piqur.com", 
                "last_name": "Natasa Cmiljanovic, Dr."
            }, 
            "facility": {
                "address": {
                    "city": "Basel", 
                    "country": "Switzerland", 
                    "zip": "4031"
                }, 
                "name": "University Hospital Basel"
            }, 
            "investigator": {
                "last_name": "Andreas Wicki, Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "PIQUR"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D)", 
            "safety_issue": "No", 
            "time_frame": "In average 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940133"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Incidence of SAEs, incidence and severity of all AEs, changes of vital signs, physical examinations, body weight, changes of routine laboratory assessments.", 
            "measure": "To determine overall safety", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "PIQUR Therapeutics AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PIQUR Therapeutics AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}